Features & Analysis

Within this section you will find in-depth analysis from Scrip World Pharmaceutical News' Executive Briefings, Market Insights and expert analysts, Peter Charlish and Ian Schofield.

MolMed reveals secret to IPO success
In a year in which the number of successful biotech IPOs fell to just three, it is hard to understand how and why even those few triumphant companies managed to raise funds in such harsh economic conditions. However, Dr Claudio Bordignon, the CEO of MolMed who oversaw the Italian biotech's €56.2 million IPO in March, recently told Scrip that the company's success came as a result of three simple factors...
Commentary - 5 January 2009

Scrip stock tracker - November 2008
November brought with it more turmoil on the financial markets. Some hoped that as we limped towards the end of 2008, the end of the beginning might be in sight. With many major economies now in recession, in this Stock Tracker for November US reporter Christopher Spillane throws some light on how these events were trickling down to the life sciences.
Stock tracker - November 2008

Japan pharma takes its place in the global market

How Japanese companies face new challenges will determine the future size and shape of their role within the global industry. Dr Michael Jones surveys changes over the past decade and analyses the current corporate and regulatory environment
Executive Briefing - Vol 1 No 10 December 2008

Senior managers need fresh skills and solid experience
Pharma’s development leaders need to have the capacity to fall in love with their molecules, and the courage to demand a divorce should the circumstances warrant it, say Dr Stevo Knezevic and Dr Peter Woods
Market Insight - 23 December 2008

Patent attack - The interim findings of the European Commission's pharmaceutical sector inquiry
The European Commission's Competition Directorate-General has revealed practices that are common to all high-tech industries, and it must not use its findings to make an ill considered attack on the patent system, says Bill Batchelor.
Commentary - 22 December 2008

Finding cash in unconventional places
Pharmaceutical companies can learn a lot from the typical cash-strapped biotech about tapping into alternative sources of development funding, explain Dr Roland Andersson, Dr Frank Deane and Eliza Kamenetsky
Market Insight - 22 December 2008

The EU pharmaceutical sector inquiry: what next?
The European Commission believes it has enough evidence from its sector inquiry to take action against some pharmaceutical companies, and patent settlements between originator companies and generic firms are likely to be a prime target. But proving that the EU competition rules have been breached will not be an easy task, say Jonathan Radcliffe and Brian Sher.
Commentary - 18 December 2008

Information to patients: the pendulum is swinging, but which way?
The debate over drug information and advertising is taking an interesting turn. Policy-makers in Europe are planning to relax the laws and allow pharmaceutical firms to provide information on their prescription drugs to EU citizens, albeit under strict conditions.
Ian Schofield - 17 December 2008

Advanced therapies regulation: perspectives from the EU
The new regulation on advanced therapy products has closed a gap in the EU regulatory framework, but how will it serve industry compared with the older system in the US? Dr Wolfgang Rehmann and Dr Gareth Morgan report
Market Insight - 17 December 2008

EU pharmaceuticals inquiry – where will the commission come knocking?
The European Commission's preliminary report on competition in the pharmaceutical sector has certainly generated a buzz in the industry. Now the dust has settled, what conclusions can be drawn from the facts and figures in this controversial 400-page document?
Ian Schofield - 10 December 2008

Previous 1 2 3 4 5 6 7 8 9 10 Next

Email to a friend

• Facebook
• digg
• del.icio.us
• furl